Evaluation of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in Japanese healthy donors: a prospective study

Is split‐dose better than single‐dose? Results of Turkish Stem Cell Coordination Center (TURKOK) donors in the era of rising biosimilar G‐CSF

“…Surprisingly, in our study, unlike some other studies, the incidence of adverse events, duration of pain, and analgesic requirement were statistically significantly higher in donors in the Tevagrastim group compared with Neupogen. 19,20 All non-severe adverse events regressed in the follow-up period after PBSC mobilization. At the same time, no serious adverse events such as acute respiratory distress-like syndrome and splenic rupture were found in our study.…”